Opus Genetics, Inc. has secured approximately $23 million in financing through a registered direct offering led by Perceptive Advisors and Balyasny Asset Management. The funds will be used to advance ophthalmic gene therapy clinical programs, including LCA5 and BEST-1 gene therapy programs. The offering includes the sale of over 3.8 million shares of common stock and pre-funded warrants. Opus Genetics plans to use the proceeds to support its operations into the second half of 2027, excluding potential future milestone payments. The offering is expected to close on November 7, 2025, subject to customary closing conditions.

Read more at GlobeNewswire: Opus Genetics Announces $23 Million Registered Direct